244 related articles for article (PubMed ID: 35896979)
1. Clinical features and
Chen D; Zhu Y; Chen Y; Zhu D; Liu Z; Li T; Liu Y; Zhao K; Su X; Li L
BMC Infect Dis; 2022 Jul; 22(1):646. PubMed ID: 35896979
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of lymphoma with
Chen J; Xu D; Sun WJ; Wang WX; Xie NN; Ruan QR; Song JX
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7187-7196. PubMed ID: 36884116
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG and (18)F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes.
Rayamajhi SJ; Mittal BR; Maturu VN; Agarwal R; Bal A; Dey P; Shukla J; Gupta D
Ann Nucl Med; 2016 Apr; 30(3):207-16. PubMed ID: 26661845
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of diffuse lymphadenopathy via various quantitative PET/CT parameters.
Silov G; Çankaya E; Karaçavuş S
Hell J Nucl Med; 2023; 26(1):47-56. PubMed ID: 37031422
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT radiomics as a tool to differentiate between reactive axillary lymphadenopathy following COVID-19 vaccination and metastatic breast cancer axillary lymphadenopathy: a pilot study.
Eifer M; Pinian H; Klang E; Alhoubani Y; Kanana N; Tau N; Davidson T; Konen E; Catalano OA; Eshet Y; Domachevsky L
Eur Radiol; 2022 Sep; 32(9):5921-5929. PubMed ID: 35385985
[TBL] [Abstract][Full Text] [Related]
7. Multiple metabolic parameters and visual assessment of
Ren Y; Liu J; Wang L; Luo Y; Ding X; Shi A; Liu J
Abdom Radiol (NY); 2020 Nov; 45(11):3569-3580. PubMed ID: 32274551
[TBL] [Abstract][Full Text] [Related]
8. CT Texture Analysis of Cervical Lymph Nodes on Contrast-Enhanced [
Kuno H; Garg N; Qureshi MM; Chapman MN; Li B; Meibom SK; Truong MT; Takumi K; Sakai O
AJNR Am J Neuroradiol; 2019 Mar; 40(3):543-550. PubMed ID: 30792253
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
11. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
12. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.
Nakayama M; Okizaki A; Ishitoya S; Sakaguchi M; Sato J; Aburano T
Ann Nucl Med; 2013 Feb; 27(2):163-9. PubMed ID: 23188388
[TBL] [Abstract][Full Text] [Related]
13. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
14. Lactate dehydrogenase levels and 18F-FDG PET/CT metrics differentiate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma.
Alkhawtani RHM; Noordzij W; Glaudemans AWJM; van Rijn RS; van der Galiën HT; Balink H; Nijland M; Adams HJA; Huls G; van Meerten T; Kwee TC
Nucl Med Commun; 2018 Jun; 39(6):572-578. PubMed ID: 29672465
[TBL] [Abstract][Full Text] [Related]
15. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
Wang J; Wang D; Zhang Q; Duan L; Tian T; Zhang X; Li J; Qiu H
J Cancer Res Clin Oncol; 2016 Apr; 142(4):859-71. PubMed ID: 26666755
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT makes a significant contribution to diagnosis of malignancy in patients with cervical lymphadenopathy: a study using optimal scale regression tests.
Ouyang L; Shi ZY; Lin ZG
Chin Med J (Engl); 2013 Feb; 126(4):659-67. PubMed ID: 23422185
[TBL] [Abstract][Full Text] [Related]
17. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
18. Correlations between maximum standardized uptake value measured via
Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q
J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
[TBL] [Abstract][Full Text] [Related]
20. Preoperative PET/CT
Chen R; Wang Y; Zhou X; Huang G; Liu J
Contrast Media Mol Imaging; 2018; 2018():5802109. PubMed ID: 30515068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]